| Clinical data | |
|---|---|
| Other names | Orgasteron acetate; MENT acetate; CDB-903; NSC-69948; U-15614; 7α-Methyl-19-nortestosterone 17β-acetate; 7α-Methylestr-4-en-17β-ol-3-one 17β-acetate |
| Routes of administration | Intramuscular injection |
| Drug class | Androgen;Anabolic steroid;Androgen ester;Progestogen;Antigonadotropin |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C21H30O3 |
| Molar mass | 330.468 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Trestolone acetate (USANTooltip United States Adopted Name; developmental code namesCDB-903,NSC-69948,U-15614; also known as7α-methyl-19-nortestosterone 17β-acetate (MENT acetate) and7α-methylestr-4-en-17β-ol-3-one 17β-acetate) is asynthetic andinjectedanabolic–androgenic steroid (AAS) and aderivative ofnandrolone (19-nortestosterone) which was never marketed.[1] It is anandrogen ester – specifically, the C17acetateester oftrestolone (7α-methyl-19-nortestosterone; MENT).[1] The medication was first described in 1963.[2]
Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |